- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Addition of Metformin to SGLT2 Inhibitors Lowers Kidney Disease Risk in Diabetes Patients: Study

Researchers have found in a new study that patients receiving a combination of metformin and SGLT2 inhibitors experienced a significant reduction in kidney disease progression and mortality compared to those treated with SGLT2 inhibitors alone. This suggests that combining these medications provides greater protective benefits for kidney health. The study was published in Cardiovascular Diabetology by Agur T. and colleagues.
Although SGLT2 inhibitors are recognized for their cardio-renal protective effects, the additional benefit of combining them with metformin has been uncertain. The current retrospective cohort study, comparing outcomes in adults with type 2 diabetes treated with SGLT2 inhibitors monotherapy and with SGLT2 inhibitors plus metformin, using data from 2016 to 2021 from Clalit Health Services, sought to determine this.
The analysis involved 45,545 patients, 6,774 patients per group after propensity score matching for balanced baseline characteristics. The median follow-up was 1,166 days. The primary outcomes examined were:
• Composite kidney outcome: 40% reduction in estimated glomerular filtration rate (eGFR) or end-stage renal disease (ESRD).
• All-cause mortality.
• Other safety outcomes like hospitalizations, acute kidney injury (AKI), and metabolic acidosis were also assessed.
Key Findings
• Patients taking combination therapy (SGLT2 inhibitors + metformin) had 26% reduced risk of all-cause mortality (aHR 0.74; 95% CI 0.64-0.84).
• Combination therapy lowered the risk of progression of kidney disease (aHR 0.65; 95% CI 0.48-0.87), even when mortality was considered as a competing risk (aHR 0.67; 95% CI 0.5-0.9).
• Risk of hospitalization was marginally decreased with combination therapy (aHR 0.93; 95% CI 0.87-0.99).
• Acute kidney injury episodes were lower in the combination group (aHR 0.72; 95% CI 0.54-0.96).
• Metabolic acidosis episodes were 42% lower in combination therapy patients (aHR 0.58; 95% CI 0.4-0.83).
This research provides compelling evidence that metformin combination with SGLT2 inhibitors dramatically cuts mortality and development of kidney disease in type 2 diabetes. Healthcare clinicians must prioritize combination therapy to improve patient outcomes, regardless of glycemic control and pre-existing cardio-renal risk factors.
Reference:
Dr Riya Dave has completed dentistry from Gujarat University in 2022. She is a dentist and accomplished medical and scientific writer known for her commitment to bridging the gap between clinical expertise and accessible healthcare information. She has been actively involved in writing blogs related to health and wellness.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751